湖南九典制药股份有限公司（以下简称"公司"）于 2025 年 2 月 17 日召开 第四届董事会第九次会议，审议通过了《关于回购公司股份方案的议案》，同意 公司通过集中竞价交易方式以自有资金和股票回购专项贷款资金回购部分社会 公众股份，用于后期实施股权激励计划。本次回购的资金总额不低于人民币 10,000 万元且不超过人民币 15,000 万元，回购价格不超过人民币 24.98 元/股， 实施期限为自董事会审议通过回购股份方案之日起 12 个月内。具体内容详见公 司在巨潮资讯网披露的《回购股份报告书》（公告编号：2025-012）等相关公告。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等有关 规定，回购期间公司应当在每个月的前三个交易日内披露截至上月末的回购进展 情况。现将公司回购进展情况公告如下： 本公司及董事会全体成员保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 | 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2025-071 ...

| 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2025-070 | 湖南九典制药股份有限公司 关于 2025 年第三季度可转换公司债券转股情况的公告 经深圳证券交易所（以下简称"深交所"）同意，公司可转债于 2023 年 10 月 13 日起在深交所挂牌交易，债券简称：九典转 02，债券代码：123223。 根据《深圳证券交易所创业板股票上市规则》和《湖南九典制药股份有限公 司创业板向不特定对象发行可转换公司债券募集说明书》的规定，公司可转债的 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、九典转02转股期限为2024年3月21日至2029年9月14日，最新转股价格为 14.95元/股。 2、2025年第三季度，共有116张九典转02完成转股，对应票面金额为11,600 元，转股数量为774股。 3、截至2025年第三季度末，九典转02剩余2,052,798张，对应票面金额为 205,279,800元。 根据《深圳证券交易 ...

Group 1: Strategic Focus and Innovation - The company is fully transforming to focus on innovative drug research and development, with a core direction in chemical and traditional Chinese medicine innovation [2] - Key therapeutic areas include pain management, focusing on peptide and small molecule drugs, and oncology, with a focus on PDC drug development [2] - The company employs a dual approach of independent research and project acquisition to build core technological barriers and accelerate innovation results [3] Group 2: Product Launch and Market Expectations - The ketoprofen gel patch was approved for market launch in 2023 and has entered the national medical insurance directory, being the first generic product in the market [4] - The company has optimistic market expectations for the ketoprofen gel patch and has developed new sales strategies focusing on external markets [4] Group 3: Research and Development Investment - The estimated R&D expenditure for 2025 is projected to be between 250 million and 300 million yuan [5] Group 4: Employee Incentives and Governance - The company is implementing a share repurchase plan to support future equity incentive plans, aiming to enhance governance and align interests among stakeholders [6] Group 5: New Product Highlights - The newly introduced innovative drug JIJ02 gel has broad-spectrum antibacterial properties, low cost, and is expected to have significant market competitiveness [7][8] - JIJ02 gel is anticipated to complete Phase I clinical trials by mid-next year and will initiate Phase II trials thereafter [8] Group 6: Pricing and Procurement - The company is currently in the bidding phase for the 11th batch of national drug procurement, with submission of application materials and public pricing information due by October 21 [8]

Core Viewpoint - The company announced the completion of changes to its registered capital and the revision of related articles, following the approval at the first extraordinary shareholders' meeting of 2025 held on September 9, 2025 [1] Group 1 - The company has completed the business registration change procedures and obtained a new business license issued by the Changsha Market Supervision Administration [1]

| 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2025-069 | 湖南九典制药股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于2025年9月9日召开2025 年第一次临时股东会，审议通过了《关于变更注册资本及修订<公司章程>的议案》， 具体内容详见公司在巨潮资讯网上披露的相关公告。 统一社会信用代码：91430100722520761D 类型：股份有限公司（上市、自然人投资或控股） 法定代表人：朱志宏 注册资本：伍亿零贰拾壹万贰仟叁佰伍拾伍元整 成立日期：2001 年 1 月 19 日 住所：长沙市浏阳经济技术开发区健康大道 1 号 经营范围：药品、二类医疗器械、消毒剂、化工产品、卫生用品、化妆品、 保健品、保健食品、食品、特殊医学用途配方食品、特殊膳食食品、一类医疗器 械、中医药、生物制品、植物提取物的研发；化学药品制剂、化学药品原料药、 生物药品、 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of two drugs, indicating progress in its research and development efforts [1] Group 1: Clinical Trials - The approved clinical trials include JIZM01 for closed soft tissue contusions and joint sprains [1] - The second trial is for JIZM02, which targets shoulder periarthritis [1]

JIZM02功能主治为：祛风除湿、活血通络、行气止痛。用于肩关节周围炎风湿痹痛证，症见肩部疼 痛，肿胀，屈伸不利。肩关节周围炎的治疗原则是针对病症的不同时期或症状严重程度采取相应的治疗 措施，包括药物治疗、物理治疗、针灸、针刀及手术治疗等。常用的治疗药物为非甾体抗炎药及中成药 制剂，如消尔痛酊、蟾马正痛酊、骨痛灵酊等。JIZM02组方精炼，无毒性药材，可为该类患者提供一 种安全有效的治疗方式。 JIZM01和JIZM02获得临床试验资格对公司的财务状况、经营业绩不构成重大影响。根据我国药品注册 相关的法律法规要求，药物在获得药物临床试验批准通知书后，尚需开展临床试验并经国家药监局审 评、审批通过后方可生产上市。 格隆汇9月24日丨九典制药(300705.SZ)公布，近日收到国家药品监督管理局签发的《药物临床试验批准 通知书》，在完成相关准备工作后将开展临床试验研究。JIZM01功能主治为：活血通络，消肿止痛。 用于闭合性软组织损伤引起的疼痛、肿胀、瘀斑、功能障碍。在临床应用中，软组织损伤主要治疗方式 以局部给药为主，常用药物有云南白药、红花油、活络油、消痛贴膏、少林风湿跌打膏等。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of two drugs, indicating progress in its research and development efforts [1] Group 1 - The company has obtained a clinical trial approval notice for JIZM01, which is intended for the treatment of closed soft tissue contusions and joint sprains [1] - The clinical trial for JIZM02 has been approved, targeting adhesive capsulitis of the shoulder [1]

Core Viewpoint - Jizhen Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of drugs JIZM01 and JIZM02, indicating progress in its research and development efforts [1] Group 1: Company Developments - Jizhen Pharmaceutical announced on September 24 that it has obtained the clinical trial approval for drugs JIZM01 and JIZM02 [1] - JIZM01 is intended for the treatment of closed soft tissue contusions and joint sprains [1] - JIZM02 is aimed at treating periarthritis of the shoulder [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of two drugs, JIZM01 and JIZM02, targeting specific medical conditions [1] Group 1: Drug Information - JIZM01 is intended for the treatment of closed soft tissue contusions and joint sprains [1] - JIZM02 is designed for shoulder periarthritis [1] Group 2: Regulatory Approval - The approval was granted in accordance with the Drug Administration Law of the People's Republic of China and relevant regulations [1] - The company will commence clinical trial research after completing the necessary preparatory work [1]